Gene transfer can be achieved in the adult rat heart in vivo by direct injection of plasmid DNA. In this report we define the spatial and temporal limits of reporter gene expression after a single intracardiac injection. pRSVCAT (100 ,ug), in which the Rous sarcoma virus long terminal repeat is fused to the chloramphenicol acetyltransferase reporter gene, and pcaMHCluc (100 pug), in which the c-cardiac myosin heavy chain promoter is fused to the firefly luciferase gene, were injected into hearts, and reporter gene activities were assayed at various times. Both chloramphenicol acetyltransferase and luciferase were detectable in 100% of the rats from 1 to 7 days, in 60% of the rats from 17 to 23 days, and in 30% of the rats from 38 to 60 days after injection. Reporter gene activity was largely limited to a 1-2-mm region of the ventricle surrounding the injection site. Closed circular DNA was far more effective than linear DNA in transfecting cells in vivo. The relative strengths of three different promoters, Rous sarcoma virus long terminal repeat, c-myosin heavy chain, and cal-antitrypsin, all fused to the luciferase reporter gene were determined. The constitutive viral promoter was -20-fold more active than the cardiac-specific cellular promoter, and the liver-specific cellular promoter was not active at all in the cardiac environment. Thus, direct injection of genes into the heart offers a simple and powerful tool with which to assess the behavior of genes in vivo. However, the potential of the technique to effect a phenotypic change in the heart is currently limited by the temporal and geographic extent of transfection. (Circulation Research 1992;70:193-198) 
It has previously been demonstrated that reporter genes linked to viral and cellular promoters can be expressed after injection of plasmid DNA into the hearts of adult rats in vivo. [1] [2] [3] Although this technique suggests a simple approach to somatic gene therapy, its utility is dependent on several parameters. One of these is the stability of the transfected gene. Acsadi et a12 recently reported that reporter genes coupled to viral promoters could not be detected in adult cardiac muscle 3 weeks after injection, suggesting that cardiac gene transfer may not be stable. In contrast, Lin et a13 were able to detect reporter gene activity up to 3-4 months after cardiac injection in a small number of animals. Whether the introduced gene is episomal may affect (either positively or negatively) the stability of muscle gene transfer, and the postmitotic state of adult muscle cells may prevent introduced genes from integrating into chromosomes. In fact, Wolff et a14 have suggested that, both in heart and skeletal muscle, directly transfected genes are episomal.
A second consideration for cardiac gene therapy is the spatial extent of transfection after a single injection. Although this has not been investigated in great depth, the precise number of cells transfected after a single injection appears to be small, based on the extent of ,3-galactosidase staining in tissue sections from hearts injected with this reporter gene.2, 3 Acsadi et a12 have shown that no reporter gene activity can be detected in atria after intraventricular injections.
In the present study, we sought to further define some of the parameters of cardiac gene transfer. Specifically, we determined the time course and geographic extent of gene expression after a single intracardiac injection. In addition, we asked whether the state of the injected DNA, either linear or circular, influenced its expression. Finally, we determined the relative strengths of a constitutive viral promoter, a cardiacspecific cellular promoter, and a liver-specific promoter. Transcription from the viral long terminal repeat (LTR) was -20-fold higher than that derived from the cardiac promoter, but no transcription resulted from the liver-specific promoter. Figure 1 . No reporter gene activity was detected 2 hours after injection; however, at 1 day all injected hearts showed both CAT and luciferase activities. The levels of expression continued to rise and reached maximal levels 7-10 days after injection. All injected hearts showed significant reporter gene activities up to this point. At subsequent time points, some of the hearts showed no detectable reporter gene activities: four of 10 hearts from 17 to 23 days and seven of 10 hearts from 38 to 60 days. Southern analysis (not shown) of HindIII digests of cellular DNA suggested that the exogenous genes were episomal.
We determined the ratio of luciferase activity to CAT activity in hearts coinjected with pRSVCAT and paMHCluc as a function of time in order to compare the behavior of these two reporter genes. In general, this ratio was constant over the first 2 weeks after injection: 424±67 in samples from 1 to 2 days versus 484±104 in samples from 7 to 23 days. In the hearts expressing the reporter genes at later time points (from 38 to 60 days). the ratio of luciferase to CAT activity fell significantly to 77±+20.
To determine the spatial extent of expression of injected genes in cardiac muscle, we injected the apical portions of individual hearts with a single 50-,ul bolus of pRSVluc, a plasmid containing the luciferase reporter gene coupled to the constitutive RSV-LTR. Five days after injection, the rats were killed, and the hearts were cut into 1-mm sections from apex to base. These sections were then assayed individually for the presence of luciferase activity. Data from two hearts are shown in Figure 2 and indicate that 90% of the expression of the luciferase gene was restricted to two 1-mm sections surrounding the injection site, although very low levels of activity were seen in two other 1-mm sections, so that some minimal activity was detectable over 40% of the long axis of the ventricle. No reporter gene activity was seen in the atria.
To assess whether the state of the injected DNA influenced its expression, we compared luciferase activity after injection with linear versus closed circular DNA. paMHCluc was digested to completion with Xmn I, which does not disrupt the promoter and coding regions of the plasmid, and 100 ,g of this linear molecule was coinjected with 100 jig closed circular pRSVCAT (as an internal control) in four rats and compared with the uncut circular plasmid, which was also coinjected with pRSVCAT in a similar number of rats. Figure 3 shows the percent CAT conversions, luciferase activities, and luciferase/CAT ratios in these rats. Luciferase/CAT ratios ( Figure 3C ) were 50-100-fold greater in those rats injected with circular DNA than in rats injected with linear DNA, demonstrating that the linear molecule was poorly expressed relative to the closed circular plasmid. CAT activities tended to be lower in the rats concomitantly injected with the linear molecule ( Figure 3B ), suggesting that this interfered with pRSVCAT uptake and/or transcription.
Finally, we determined the relative strengths of three promoters linked to the luciferase reporter gene in the heart. The promoters were derived from the RSV-LTR, the rat a-cardiac myosin heavy chain gene, and the liver-specific mouse a1-antitrypsin gene An additional piece of information provided in the present study is the first quantitative assessment of the relative strengths of promoters in vivo. Our data indicate that the constitutive RSV-LTR is -20-fold more active than a cardiac-specific cellular promoter. The absence of any discernible promoter activity after injection of a liver-specific cellular promoter in the heart confirms our previous demonstration' that directly injected cellular genes behave in a tissuerestricted fashion and also establishes that the heart is not a promiscuous environment for gene expression via this technique. An additional finding from this experiment is that competition for transcription factors likely occurs when two strong promoters are coinjected into cardiac muscle. This is striking when contrasting CAT activities in the rats injected with pRSVluc/ pRSVCAT (3.3% conversion) and paMHCluc/ pRSVCAT (15.0% conversion) but is also evident when comparing these two groups with the rats injected with palATluc/pRSVCAT (27.2% conversion Figures 3A and 3B , which show significant interanimal variability in CAT and luciferase expression after a single injection. However, when the expression of a cellular promoter (a-cardiac myosin heavy chain) is normalized to that of a constitutive promoter (RSV-LTR) as in Figure  3C , the data are remarkably consistent. The standard error of these four measurements is <15%. Similar experimental variability can be seen in the time course data shown in Figure 1 . Second, comparisons of reporter genes should be done during periods of stable gene expression. In the case of the two reporter gene constructs used in the present study, this period is 2-7 days after injection, during which time expression is consistent in all injected hearts and the ratio of CAT/luciferase is constant. At later times, the ratio of the two reporter genes decreases, which may reflect a longer half-life of the CAT protein or preferential transcription of the RSV-LTR-driven reporter gene. The half-life of these reporter genes in mammalian tissue is not known, although the halflife of luciferase expression after injection of RNA expressing the luciferase coding region in skeletal muscle is -12 hours4 and that of CAT in mammalian cells is <2 days.13 This suggests that expression of the reporter genes at later time points is the result of ongoing transcription and translation. Finally, potential interactions between plasmids must be considered. For example, competition between strong promoters probably occurs in vivo, and in the experiment comparing linear and closed circular DNA, the linear molecule appeared to inhibit either the uptake and/or the expression of the coinjected pRSVCAT.
If these caveats are acknowledged, direct injection of DNA appears to offer a simple and powerful tool with which to assess gene behavior in vivo. Future studies, aimed at extending the geographic limits of expression and maintaining the integrity of an injected plasmid, may allow the development of a strategy for somatic cell gene therapy in the heart. 
